Výsledky vyhľadávania - "O'Malley, David M"

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer Autor Matei, Daniela, Filiaci, Virginia, Randall, Marcus E, Mutch, David, Steinhoff, Margaret M, DiSilvestro, Paul A, Moxley, Katherine M, Kim, Yong M, Powell, Matthew A, O’Malley, David M, Spirtos, Nick M, Small, William, Tewari, Krishnansu S, Richards, William E, Nakayama, John, Matulonis, Ursula A, Huang, Helen Q, Miller, David S

“…After a median of nearly 4 years of follow-up, the use of radiotherapy combined with chemotherapy in patients with stage III or IVA endometrial carcinoma was…”
Získať plný text

PARP Inhibitors in Ovarian Cancer: A Review Autor O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.

“…Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a…”
Získať plný text

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review Autor Richardson, Debra L, Eskander, Ramez N, O'Malley, David M

“…Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based…”
Zistit podrobnosti o prístupe

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study Autor O'Malley, David M, Bariani, Giovanni Mendonca, Cassier, Philippe A, Marabelle, Aurelien, Hansen, Aaron R, De Jesus Acosta, Ana, Miller, Jr, Wilson H, Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele

“…Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch…”
Zistit podrobnosti o prístupe

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study Autor Moore, Kathleen N, Martin, Lainie P, O'Malley, David M, Matulonis, Ursula A, Konner, Jason A, Perez, Raymond P, Bauer, Todd M, Ruiz-Soto, Rodrigo, Birrer, Michael J

“…Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate…”
Zistit podrobnosti o prístupe

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) Autor Monk, Bradley J, Parkinson, Christine, Lim, Myong Cheol, O'Malley, David M, Oaknin, Ana, Wilson, Michelle K, Coleman, Robert L, Lorusso, Domenica, Bessette, Paul, Ghamande, Sharad, Christopoulou, Athina, Provencher, Diane, Prendergast, Emily, Demirkiran, Fuat, Mikheeva, Olga, Yeku, Oladapo, Chudecka-Glaz, Anita, Schenker, Michael, Littell, Ramey D, Safra, Tamar, Chou, Hung-Hsueh, Morgan, Mark A, Drochýtek, Vít, Barlin, Joyce N, Van Gorp, Toon, Ueland, Fred, Lindahl, Gabriel, Anderson, Charles, Collins, Dearbhaile C, Moore, Kathleen, Marme, Frederik, Westin, Shannon N, McNeish, Iain A, Shih, Danny, Lin, Kevin K, Goble, Sandra, Hume, Stephanie, Fujiwara, Keiichi, Kristeleit, Rebecca S

“…ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population,…”
Zistit podrobnosti o prístupe

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study Autor Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

“…BackgroundDostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We…”
Získať plný text

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer Autor Chan, John K, Brady, Mark F, Penson, Richard T, Huang, Helen, Birrer, Michael J, Walker, Joan L, DiSilvestro, Paul A, Rubin, Stephen C, Martin, Lainie P, Davidson, Susan A, Huh, Warner K, O’Malley, David M, Boente, Matthew P, Michael, Helen, Monk, Bradley J

“…The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received…”
Získať plný text

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu Autor Fader, Amanda N, Roque, Dana M, Siegel, Eric, Buza, Natalia, Hui, Pei, Abdelghany, Osama, Chambers, Setsuko K, Secord, Angeles Alvarez, Havrilesky, Laura, O'Malley, David M, Backes, Floor, Nevadunsky, Nicole, Edraki, Babak, Pikaart, Dirk, Lowery, William, ElSahwi, Karim S, Celano, Paul, Bellone, Stefania, Azodi, Masoud, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Schwartz, Peter E, Santin, Alessandro D

“…Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human…”
Zistit podrobnosti o prístupe

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study Autor O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona

“…Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising…”
Zistit podrobnosti o prístupe

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study Autor Oaknin, Ana, Pothuri, Bhavana, Gilbert, Lucy, Sabatier, Renaud, Brown, Jubilee, Ghamande, Sharad, Mathews, Cara, O'Malley, David M, Kristeleit, Rebecca, Boni, Valentina, Gravina, Adriano, Banerjee, Susana, Miller, Rowan, Pikiel, Joanna, Mirza, Mansoor R, Dewal, Ninad, Antony, Grace, Dong, Yuping, Zografos, Eleftherios, Veneris, Jennifer, Tinker, Anna V

“…This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC),…”
Zistit podrobnosti o prístupe

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer Autor Grisham, Rachel, Monk, Bradley J, Van Nieuwenhuysen, Els, Moore, Kathleen Nadine, Fabbro, Michel, O'Malley, David M, Oaknin, Ana, Thaker, Premal, Oza, Amit M, Colombo, Nicoletta, Gershenson, David, Aghajanian, Carol A, Choi, Chel Hun, Lee, Yeh Chen, Mirza, Mansoor Raza, Coleman, Robert L, Cobb, Lauren, Harter, Philipp, Lustgarten, Stephanie, Youssoufian, Hagop, Banerjee, Susana

“…There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and…”
Získať plný text

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum Autor Monk, Bradley J, Grisham, Rachel N, Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L, Hilpert, Felix, Oza, Amit M, Westermann, Anneke, Oehler, Martin K, Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N, Christy-Bittel, Janna, Del Campo, Josep M, Berger, Regina, Marth, Christian, Sehouli, Jalid, O'Malley, David M, Churruca, Cristina, Boyd, Adam P, Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace

“…Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are…”
Zistit podrobnosti o prístupe

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer Autor Aghajanian, Carol, Filiaci, Virginia, Dizon, Don S., Carlson, Jay W., Powell, Matthew A., Secord, Angeles Alvarez, Tewari, Krishnansu S., Bender, David P., O'Malley, David M., Stuckey, Ashley, Gao, JianJiong, Dao, Fanny, Soslow, Robert A., Lankes, Heather A., Moore, Kathleen, Levine, Douglas A.

“…Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating…”
Získať plný text

Antibody-drug conjugates for the treatment of ovarian cancer Autor Calo, Corinne A., O'Malley, David M.

“…Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience…”
Získať plný text

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial Autor Coleman, Robert L, Brady, Mark F, Herzog, Thomas J, Sabbatini, Paul, Armstrong, Deborah K, Walker, Joan L, Kim, Byoung-Gie, Fujiwara, Keiichi, Tewari, Krishnansu S, O'Malley, David M, Davidson, Susan A, Rubin, Stephen C, DiSilvestro, Paul, Basen-Engquist, Karen, Huang, Helen, Chan, John K, Spirtos, Nick M, Ashfaq, Raheela, Mannel, Robert S

“…Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this…”
Získať plný text

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer Autor Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

“…BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors…”
Získať plný text

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study Autor Hensley, Martee L, Enserro, Danielle, Hatcher, Helen, Ottevanger, Petronella B, Krarup-Hansen, Anders, Blay, Jean-Yves, Fisher, Cyril, Moxley, Katherine M, Lele, Shashikant B, Lea, Jayanthi S, Tewari, Krishnansu S, Thaker, Premal H, Zivanovic, Oliver, O'Malley, David M, Robison, Katina, Miller, David S

“…We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma. Women with…”
Zistit podrobnosti o prístupe

Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin Autor Sakaue, Takahiko, Dorayappan, Kalpana Deepa Priya, Zingarelli, Roman, Khadraoui, Wafa, Anbalagan, Muralidharan, Wallbillich, John, Bognar, Balazs, Wanner, Ross, Cosgrove, Casey, Suarez, Adrian, Koga, Hironori, Maxwell, G. Larry, O’Malley, David M., Cohn, David E., Selvendiran, Karuppaiyah

“…Endometrial cancer (EC) is the leading gynecologic malignancy in the United States with obesity implicated in 57% of cases. This research investigates the…”
Získať plný text

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Autor Swisher, Elizabeth M., Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L., Aghajanian, Carol, Konecny, Gottfried E., O’Malley, David M., Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-may, Wahner Hendrickson, Andrea E., Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S., Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H., Elvin, Julia A., Lin, Douglas I., Chambers, Setsuko K., Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L., Lin, Kevin K., McNeish, Iain A.

“…ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post…”
Získať plný text